Is BAYRY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Closing out the Roundup litigation, with revenue (fy2025) at ~EUR 45.6 billion (~$51 billion). The bear case rests on litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. Analysts covering it are spread from $15.30 to $16.68, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $15.30, +22.7% from the $12.47 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Closing out the Roundup litigation. The single largest swing factor for Bayer is legal, not operational. The most optimistic analyst target on BAYRY is $16.68, +33.8% from the $12.47 price. That figure is only reachable if this thesis works close to its best case.

Litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework. Pharma faces continued generic erosion of Xarelto and Eylea, and pipeline setbacks (as with the earlier OCEANIC-AF failure of asundexian in atrial fibrillation) can reset expectations quickly. Crop Science is cyclical and exposed to farm economics, weather, trade policy and low-cost generic chemistry. Net financial debt near EUR 30 billion limits flexibility, and credit rating pressure would raise funding costs. For US holders of BAYRY there is also euro currency exposure, German dividend withholding tax, and thinner OTC trading than the Xetra listing. The most pessimistic published target is $15.30, +22.7% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Leverkusen-based life sciences group spanning crop science, prescription drugs and consumer health, still working through Roundup litigation.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Closing out the Roundup litigation) stalling in the reported numbers rather than in the narrative, the risk above (litigation remains the core risk: the class settlement could be delayed, challenged, or terminated if opt-outs exceed Bayer's threshold, and PCB claims and other Monsanto-era cases sit outside the glyphosate framework) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

BAYRY is the ticker for Bayer AG's sponsored American Depositary Receipt, which trades over the counter in the US rather than on the NYSE or Nasdaq. Bayer's primary listing is on the Frankfurt Stock Exchange's Xetra platform under the ticker BAYN, where it is part of the DAX index. The ADR lets US investors hold an economic interest in Bayer in US dollars through a regular brokerage account, with settlement and dividends handled in dollars. It is the same company: the drug, crop science and consumer health businesses described above. The ADR price simply reflects the German share price converted into dollars and divided by the ADR ratio.

Four BAYRY ADRs represent one Bayer ordinary share, so at ~EUR 44 per share and an exchange rate near $1.11 to $1.12 per euro, each ADR should trade around a quarter of the dollar value of one share, roughly $12. Because the underlying shares are priced in euros, BAYRY moves with both Bayer's share price and the EUR/USD exchange rate: a stronger euro lifts the ADR even if the German shares are flat. Dividends are declared in euros, converted to dollars by the depositary, and subject to German withholding tax (a headline rate of ~26.4%, which US investors may partly reclaim or credit under the US-Germany tax treaty's 15% rate). Depositary fees may also be deducted. OTC trading volume is thinner than in Frankfurt, so spreads can be wider.

Bayer closed its ~$63 billion acquisition of Monsanto in 2018, just as US juries began awarding large verdicts to plaintiffs alleging that Roundup's active ingredient glyphosate caused non-Hodgkin lymphoma. Bayer has said the science and regulators support glyphosate's safety, but the litigation grew to well over 100,000 claims, and Bayer set aside more than $10 billion across successive settlements. Monsanto-era PCB claims added to the bill. At the same time, Xarelto approached patent expiry, a 2023 trial failure for asundexian removed a hoped-for successor in atrial fibrillation, and crop protection prices fell. The combination drove the share price to multi-decade lows by 2024 and 2025 and led Bayer to cut its dividend to the legal minimum.